Cargando…
Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19
Favipiravir is an antiviral drug that is expected to have a therapeutic effect on SARS-CoV2 infection. Teratogenicity and hyperuricemia are known as the main side effects of favipiravir, but little is known about other side effects. This report describes a case of cholestatic liver injury induced by...
Autores principales: | Yamazaki, Shingo, Suzuki, Takaaki, Sayama, Misa, Nakada, Taka-aki, Igari, Hidetoshi, Ishii, Itsuko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833994/ https://www.ncbi.nlm.nih.gov/pubmed/33402301 http://dx.doi.org/10.1016/j.jiac.2020.12.021 |
Ejemplares similares
-
Adverse effect investigation using application software after vaccination against SARS-CoV-2 for healthcare workers
por: Yamazaki, Shingo, et al.
Publicado: (2022) -
Favipiravir/meropenem/vancomycin: Cholestatic liver injury following off-label use: case report
Publicado: (2021) -
The Role of Inflammation in Cholestatic Liver Injury
por: Chen, Jie, et al.
Publicado: (2023) -
Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021) -
Kratom-Induced Cholestatic Liver Injury and Its Conservative Management
por: Fernandes, Christopher T., et al.
Publicado: (2019)